We are pleased to announce the successful commissioning of our state-of-the-art I-131 Oral Solution and Capsule manufacturing facility in Manesar, Haryana, in June 2024. This advanced unit has been established within the same premises as our existing 99mTc Generator production facility, enabling integrated operations and enhanced production efficiency.

The facility has been developed to cater to the growing demand of the nuclear medicine fraternity and to ensure a reliable and uninterrupted supply of I-131 for therapeutic applications.

Designed with enhanced shielding systems and automated handling technologies, it supports a maximum processing capacity of up to 60 Ci at a time, making it one of the highest-capacity I-131 production units in the region.

In addition to scaling production, the facility is equipped to meet the customised requirements of customers, offering flexible dosing formats and tailored activity levels to support diverse clinical protocols.

This milestone strengthens our commitment to delivering consistent, GMP-compliant radiopharmaceuticals for thyroid cancer and hyperthyroidism treatments nationwide.